title: Protection against influenza A virus infection in mice by oral immunization with a polyvalent bacterial lysate.
abstract: A study is presented which investigated whether oral immunization with a polyvalent bacterial lysate (Paspat oral) can sufficiently enhance cell-mediated defense mechanisms to protect mice against influenza A virus infection. It was found that oral immunization reduced mortality due to influenza A infection with 15-70%, depending on the quantity of virus administered and and the moment of infection. Cyclosporin A severely reduced the protective effect of oral immunization, suggesting that a major effect of oral immunization in these studies is T-cell activation. The effect of oral immunization on macrophageal activity was evaluated by measuring cyclic-AMP in alveolar macrophages (AMs) obtained by bronchoalveolar lavage. Before infection, basal activity levels of AMs in immunized mice were significantly lower than in controls. Five days after infection, however, basal activity level of AMs in immunized mice was significantly higher than AM activity in controls. Stimulation of AMs with PGE2 significantly reduced cellular activity in both groups, before and after infection. However, cellular activity of AMs from immunized animals was less reduced than cellular activity of control macrophages. Activity of AMs of immunized animals was significantly more reduced by histamine than activity of control macrophages. It is concluded that oral immunization with Paspat oral stimulates T-cell-dependent immune mechanisms, resulting in protection against influenza A virus infection in mice.
authors.affiliation: Department of Anesthesiology, Erasmus University Rotterdam, The Netherlands.
authors.forename: G J
authors.initials: GJ
authors.lastname: Van Daal
authors.forename: F D
authors.initials: FD
authors.lastname: Beusenberg
authors.forename: K L
authors.initials: KL
authors.lastname: So
authors.forename: R B
authors.initials: RB
authors.lastname: Fiévez
authors.forename: M J
authors.initials: MJ
authors.lastname: Sprenger
authors.forename: J W
authors.initials: JW
authors.lastname: Mouton
authors.forename: A
authors.initials: A
authors.lastname: Van 't Veen
authors.forename: B
authors.initials: B
authors.lastname: Lachmann
mesh_terms: D000284:Administration, Oral; D000818:Animals; D000942:Antigens, Bacterial / Q000008:administration & dosage*; D000242:Cyclic AMP / Q000378:metabolism; D007111:Immunity, Cellular; D007114:Immunization; D009980:Influenza A virus / Q000276:immunology; D008264:Macrophages / Q000276:immunology / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009976:Orthomyxoviridae Infections / Q000276:immunology / Q000517:prevention & control*; D011650:Pulmonary Alveoli / Q000276:immunology
chemical_list: D000942:Antigens, Bacterial; C038593:Paspat; D000242:Cyclic AMP